Home Cart Sign in  
Chemical Structure| 2647530-73-0 Chemical Structure| 2647530-73-0

Structure of Ensitrelvir
CAS No.: 2647530-73-0

Chemical Structure| 2647530-73-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ensitrelvir is an orally active non-covalent SARS-CoV-2 3CL protease inhibitor with an IC50 of 13 nM, showing potential against COVID-19.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ensitrelvir

CAS No. :2647530-73-0
Formula : C22H17ClF3N9O2
M.W : 531.88
SMILES Code : N(C=1N(CC2=C(F)C=C(F)C(F)=C2)C(=O)N(CC=3N=CN(C)N3)C(=O)N1)C4=CC=5C(C=C4Cl)=NN(C)C5
MDL No. :N/A
InChI Key :QMPBBNUOBOFBFS-UHFFFAOYSA-N
Pubchem ID :162533924

Safety of Ensitrelvir

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

Description
Ensitrelvir (S-217622) represents the first orally administered non-covalent, non-peptidic inhibitor of the SARS-CoV-2 3CL protease, with an IC50 of 13 nM[1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT06775730 Healthy Adult Female Participa... More >>nts Less << PHASE1 RECRUITING 2025-02-27 Early Phase Clinical Unit Los ... More >>Angeles, Glendale, California, 91206, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.88mL

0.38mL

0.19mL

9.40mL

1.88mL

0.94mL

18.80mL

3.76mL

1.88mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories